Key result
Chagas cardiomyopathy was associated with increased all-cause mortality or heart transplantation compared to non-Chagas cardiomyopathy (36% vs 10%; HR 4.46; 95% CI 1.8-10.8; P=0.001).
Why the study?
Does Chagas cardiomyopathy increase morbidity and mortality in Latin American immigrants with nonischemic cardiomyopathy compared to non-Chagas cardiomyopathy?
Cohort (n=135)
No
Does Chagas cardiomyopathy increase morbidity and mortality in Latin American immigrants with nonischemic cardiomyopathy compared to non-Chagas cardiomyopathy?
Hazard Ratio: 4.46 (95% CI 1.8–10.8)
Absolute Event Rate: 36% vs 10%
p-value: p=0.001
Chagas cardiomyopathy is highly prevalent among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles and is associated with significantly worse clinical outcomes compared to non-Chagas cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
May warrant Chagas screening in at-risk immigrants with cardiomyopathy; leaves open whether targeted therapies alter outcomes.
Traina et al. (2015) conducted a cohort in Nonischemic cardiomyopathy (n=135). Chagas cardiomyopathy vs. Non-Chagas cardiomyopathy was evaluated on All-cause mortality or heart transplantation (HR 4.46, 95% CI 1.8-10.8, p=0.001). Chagas cardiomyopathy was associated with increased all-cause mortality or heart transplantation compared to non-Chagas cardiomyopathy (36% vs 10%; HR 4.46; 95% CI 1.8-10.8; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: